checkAd

     137  0 Kommentare The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis - Seite 4

    Contacts:
    Investor Relations:
    Heather Rowe Armstrong
    Vice President, Investor Relations & Corporate Communications
    harmstrong@arcutis.com
    805-418-5006, Ext. 740

    Media Relations:
    Mike Beyer
    Sam Brown, Inc.
    mikebeyer@sambrown.com
    312-961-2502

    Lesen Sie auch

    Phase 2B Trial of Roflumilast Cream (ARQ-151) for the Treatment of Chronic Plaque Psoriasis: http://ml.globenewswire.com/Resource/Download/6a25f0f8-31fc-439d-bcf8- ...


    Aktuelle Themen


    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis - Seite 4 Data demonstrate potential “Best in Class” topical PDE4 inhibitor roflumilast significantly improves chronic plaque psoriasisPhase 3 topline data anticipated first half of 2021 WESTLAKE VILLAGE, Calif., July 15, 2020 (GLOBE NEWSWIRE) - Arcutis …